Patents Assigned to Sequoia Pharmaceuticals
-
Publication number: 20110112137Abstract: Compositions and methods of treating viral infections are provided. More particularly, compositions including a combination of protease inhibitors and cytochrome p450 enzyme inhibitors are provided. Methods of using the compositions for treatment of diseases or disorders caused by a virus such as HIV infections are also provided.Type: ApplicationFiled: February 23, 2009Publication date: May 12, 2011Applicant: Sequoia Pharmaceuticals, Inc.Inventors: Michael Eissenstat, Dehui Duan, John W. Erickson
-
Publication number: 20110098237Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.Type: ApplicationFiled: February 23, 2009Publication date: April 28, 2011Applicant: Sequoia Pharmaceuticals, Inc.Inventors: Michael Eissenstat, Dehui Duan, Sergi Gulnik, John W. Erickson
-
Publication number: 20110098236Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.Type: ApplicationFiled: February 23, 2009Publication date: April 28, 2011Applicant: Sequoia Pharmaceuticals, Inc.Inventors: Michael Eissenstat, Dehui Duan
-
Patent number: 7807845Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.Type: GrantFiled: March 11, 2005Date of Patent: October 5, 2010Assignee: Sequoia Pharmaceuticals, Inc.Inventors: Michael Eissenstat, Tatiana Guerassina
-
Publication number: 20100056596Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.Type: ApplicationFiled: March 20, 2009Publication date: March 4, 2010Applicant: Sequoia PharmaceuticalsInventors: Michael Eissenstat, Andrey Topin, Greg Delahanty, Gnana Ravi Rajendran
-
Publication number: 20100009935Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.Type: ApplicationFiled: July 16, 2009Publication date: January 14, 2010Applicant: SEQUOIA PHARMACEUTICALSInventors: John W. Erickson, Michael Eissenstat, Abelardo Silva, Sergei Gulnik
-
Publication number: 20090143408Abstract: Methods of inhibiting cytochrome P450 2D6 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450 2D6. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 2D6 enzymes.Type: ApplicationFiled: November 26, 2008Publication date: June 4, 2009Applicant: Sequoia Pharmaceuticals, Inc.Inventors: Michael EISSENSTAT, Dehui Duan, Ji-Hye Kang
-
Patent number: 7507763Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.Type: GrantFiled: July 21, 2006Date of Patent: March 24, 2009Assignee: Sequoia PharmaceuticalsInventors: Michael Eissenstat, Andrey Topin, Greg Delahanty, Gnana Ravi Rajendran
-
Publication number: 20080227744Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.Type: ApplicationFiled: March 17, 2008Publication date: September 18, 2008Applicant: SEQUOIA PHARMACEUTICALS, INC.Inventor: Michael Eissenstat
-
Patent number: 7378441Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.Type: GrantFiled: May 9, 2005Date of Patent: May 27, 2008Assignee: Sequoia Pharmaceuticals, Inc.Inventors: Michael Eissenstat, Andrey Topin, Greg Delahanty, Gnana Ravi Rajendran
-
Publication number: 20080113945Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.Type: ApplicationFiled: August 20, 2007Publication date: May 15, 2008Applicant: Sequoia Pharmaceuticals, Inc.Inventors: Michael Eissenstat, Dehui Duan
-
Publication number: 20070207952Abstract: The invention provides biologically active compounds that may be reacted with macromolecules, such as albumin, to form covalent linked complexes wherein the resulting complexes exhibit a desired biological activity in vivo. More specifically, the complexes are isolated complexes comprising a biologically active moiety covalently bound to a linking group and a protein. The complexes are prepared by conjugating a biologically active moiety, for example, a renin inhibitor or a viral fusion inhibitor peptide, with purified and isolated protein. The complexes have extended lifetimes in the bloodstream as compared to the unconjugated molecule, and exhibit biological activity for extended periods of time as compared to the unconjugated molecule. The invention also provides anti-viral compounds that are inhibitors of viral infection and/or exhibit anti-fusiogenic properties.Type: ApplicationFiled: March 24, 2004Publication date: September 6, 2007Applicant: SEQUOIA PHARMACEUTICALSInventors: Abelardo Silva, John Erickson, Michael Eissenstat, Elena Afonina, Sergei Gulnik
-
Publication number: 20070185027Abstract: The invention provides compositions and methods that are useful for preventing and treating a coronavirus infection in a subject. More specifically, the invention provides peptides and conjugates and pharmaceutical compositions containing those peptides and conjugates that block fusion of a coronavirus, such as the SARS virus, to a target cell. This blocking mechanism prevents or treats a coronavirus infection, such as a SARS infaction, in a subject, such as a human subject.Type: ApplicationFiled: November 9, 2006Publication date: August 9, 2007Applicant: SEQUOIA PHARMACEUTICALS, INC.Inventors: John Erickson, Abelardo Silva
-
Publication number: 20060293286Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.Type: ApplicationFiled: July 21, 2006Publication date: December 28, 2006Applicant: Sequoia Pharmaceuticals, Inc.Inventors: John Erickson, Michael Eissenstat, Abelardo Silva, Sergei Gulnik
-
Patent number: 7151163Abstract: The invention provides compositions and methods that are useful for preventing and treating a coronavirus infection in a subject. More specifically, the invention provides peptides and conjugates and pharmaceutical compositions containing those peptides and conjugates that block fusion of a coronavirus, such as the SARS virus, to a target cell. This blocking mechanism prevents or treats a coronavirus infection, such as a SARS infection, in a subject, such as a human subject.Type: GrantFiled: April 28, 2004Date of Patent: December 19, 2006Assignee: Sequoia Pharmaceuticals, Inc.Inventors: John W. Erickson, Abelardo Silva
-
Publication number: 20060258737Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.Type: ApplicationFiled: July 21, 2006Publication date: November 16, 2006Applicant: Sequoia Pharmaceuticals, Inc.Inventors: John Erickson, Michael Eissenstat, Abelardo Silva, Sergei Gulnik
-
Publication number: 20060258627Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.Type: ApplicationFiled: July 21, 2006Publication date: November 16, 2006Applicant: Sequoia PharmaceuticalsInventors: Michael Eissenstat, Andrey Topin, Greg Delahanty, Gnana Rajendran
-
Patent number: 7109230Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.Type: GrantFiled: January 7, 2003Date of Patent: September 19, 2006Assignee: Sequoia Pharmaceuticals, Inc.Inventors: John W. Erickson, Michael Eissenstat, Abelardo Silva, Sergei Gulnik
-
Publication number: 20050267074Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.Type: ApplicationFiled: May 9, 2005Publication date: December 1, 2005Applicant: Sequoia PharmaceuticalsInventors: Michael Eissenstat, Andrey Topin, Greg Delahanty, Gnana Rajendran
-
Publication number: 20050209301Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.Type: ApplicationFiled: March 11, 2005Publication date: September 22, 2005Applicant: SEQUOIA PHARMACEUTICALSInventors: Michael Eissenstat, Tatiana Guerassina